Pfizer Discontinues Hemophilia Gene Therapy Beqvez
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia B product Beqvez.
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...
Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
A groundbreaking gene therapy has restored sight in four young children born with severe blindness due to a rare genetic ...
1don MSN
A Connecticut boy is among four children all born with severe childhood blindness who gained “life-changing improvements” to ...
Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...
At the Envision Summit 2025 in San Juan, Puerto Rico, Mike Farkas, MD, discussed gene therapy research for retinal ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback